Menu Search
Equities

Gensight Biologics SA

0RIM:LSE

Gensight Biologics SA

Actions
  • Price (EUR)0.3524
  • Today's Change0.000 / 0.00%
  • Shares traded27.27k
  • 1 Year change-39.24%
  • Beta--
Data delayed at least 20 minutes, as of Nov 13 2024 16:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Gensight Biologics SA had revenues fall -50.93% from 2.58m to 1.27m, though the company grew net income from a loss of 27.63m to a smaller loss of 26.22m.
Gross margin--
Net profit margin-2,501.00%
Operating margin-2,488.31%
Return on assets-126.79%
Return on equity--
Return on investment--
More ▼

Cash flow in EURView more

In 2023, cash reserves at Gensight Biologics SA fell by 8.48m. Cash Flow from Financing totalled 15.86m or 1,251.70% of revenues. In addition the company used 24.66m for operations while cash from investing totalled 209.00k.
Cash flow per share-0.2727
Price/Cash flow per share--
Book value per share-0.2402
Tangible book value per share-0.2408
More ▼

Balance sheet in EURView more

Gensight Biologics SA uses little or no debt in its capital structure.
Current ratio0.772
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.